17 alpha-hydroxylase deficiency differential diagnosis: Difference between revisions
Line 343: | Line 343: | ||
| rowspan="9" |Endogenous causes | | rowspan="9" |Endogenous causes | ||
![[17 alpha-hydroxylase deficiency]] | ![[17 alpha-hydroxylase deficiency]] | ||
|Mutations in the [[CYP17A1]] gene | | | ||
* Mutations in the [[CYP17A1]] gene | |||
| | | | ||
* [[Ambiguous genitalia]] in male | * [[Ambiguous genitalia]] in male | ||
Line 360: | Line 361: | ||
|- | |- | ||
![[11β-hydroxylase deficiency]] | ![[11β-hydroxylase deficiency]] | ||
|Mutations in the [[CYP11B1]] gene | | | ||
* Mutations in the [[CYP11B1]] gene | |||
| | | | ||
* [[Ambiguous genitalia]] in female | * [[Ambiguous genitalia]] in female | ||
Line 382: | Line 384: | ||
|- | |- | ||
![[Liddle's syndrome|Liddle’s syndrome]] (Pseudohyperaldosteronism type 1) | ![[Liddle's syndrome|Liddle’s syndrome]] (Pseudohyperaldosteronism type 1) | ||
|Mutation of the epithelial [[sodium]] channels ([[ENaC]]) [[gene]] in the distal [[renal tubules]] | | | ||
* Mutation of the epithelial [[sodium]] channels ([[ENaC]]) [[gene]] in the distal [[renal tubules]] | |||
| | | | ||
* [[Hypertension]] | * [[Hypertension]] | ||
Line 415: | Line 418: | ||
|- | |- | ||
!Insensitivity to [[glucocorticoids]] (Chrousos syndrome) | !Insensitivity to [[glucocorticoids]] (Chrousos syndrome) | ||
|Mutations in [[glucocorticoid receptor]] (GR) gene | | | ||
* Mutations in [[glucocorticoid receptor]] (GR) gene | |||
| | | | ||
* [[Hypertension]] | * [[Hypertension]] | ||
Line 427: | Line 431: | ||
|- | |- | ||
![[Cortisol]]-secreting adrenocortical [[carcinoma]] | ![[Cortisol]]-secreting adrenocortical [[carcinoma]] | ||
|Multifactorial | | | ||
* Multifactorial | |||
| | | | ||
Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]]) | Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]]) | ||
Line 444: | Line 449: | ||
|- | |- | ||
!Geller’s syndrome | !Geller’s syndrome | ||
|[[Mutation]] of [[mineralocorticoid]] (MR) receptor that alters its specificity and allows [[progesterone]] to bind MR | | | ||
|Severe [[hypertension]] particularly during [[pregnancy]] | * [[Mutation]] of [[mineralocorticoid]] (MR) receptor that alters its specificity and allows [[progesterone]] to bind MR | ||
| | |||
* Severe [[hypertension]] particularly during [[pregnancy]] | |||
|[[Progesterone]] has [[mineralocorticoid]] effects | |[[Progesterone]] has [[mineralocorticoid]] effects | ||
|↓ | |↓ | ||
Line 453: | Line 460: | ||
|- | |- | ||
!Gordon’s syndrome (Pseudohypoaldosteronism type 2) | !Gordon’s syndrome (Pseudohypoaldosteronism type 2) | ||
|Mutations of at least four genes have been identified, including WNK1 and WNK4 | | | ||
* Mutations of at least four genes have been identified, including WNK1 and WNK4 | |||
| | | | ||
* [[Hypertension]] | * [[Hypertension]] | ||
Line 468: | Line 476: | ||
| rowspan="4" |Exogenous causes | | rowspan="4" |Exogenous causes | ||
!Corticosteroids with mineralocorticoid activity | !Corticosteroids with mineralocorticoid activity | ||
|Fludrocortisone or fluoroprednisolone can mimic the action of aldosterone | | | ||
* Fludrocortisone or fluoroprednisolone can mimic the action of aldosterone | |||
| | | | ||
* [[Hypertension]] | * [[Hypertension]] | ||
Line 480: | Line 489: | ||
|- | |- | ||
!Licorice ingestion | !Licorice ingestion | ||
|[[Glycyrrhetinic acid]] that binds [[mineralocorticoid]] receptor and blocks 11-HSD2 at the level of classical target tissues of [[aldosterone]] | | | ||
* [[Glycyrrhetinic acid]] that binds [[mineralocorticoid]] receptor and blocks 11-HSD2 at the level of classical target tissues of [[aldosterone]] | |||
| | | | ||
* [[Hypertension]] | * [[Hypertension]] | ||
Line 492: | Line 502: | ||
|- | |- | ||
!Grapefruit | !Grapefruit | ||
|High assumption of naringenin, a component of grapefruit, can also block 11-HSD (11β- | | | ||
* High assumption of naringenin, a component of grapefruit, can also block 11-HSD (11β-hydroxysteroid dehydrogenase) | |||
| | | | ||
* [[Hypertension]] | * [[Hypertension]] |
Revision as of 13:48, 3 October 2017
17 alpha-hydroxylase deficiency Microchapters |
Differentiating 17 alpha-hydroxylase deficiency from other Diseases |
Diagnosis |
Treatment |
Case Studies |
17 alpha-hydroxylase deficiency differential diagnosis On the Web |
American Roentgen Ray Society Images of 17 alpha-hydroxylase deficiency differential diagnosis |
FDA on 17 alpha-hydroxylase deficiency differential diagnosis |
CDC on 17 alpha-hydroxylase deficiency differential diagnosis |
17 alpha-hydroxylase deficiency differential diagnosis in the news |
Blogs on 17 alpha-hydroxylase deficiency differential diagnosis |
Risk calculators and risk factors for 17 alpha-hydroxylase deficiency differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Overview
17 alpha-hydroxylase deficiency must be differentiated from diseases with primary amenorrhea and female external genitalia. Some of these causes include Pregnancy, androgen insensitivity syndrome, 3beta-hydroxysteroid dehydrogenase type 2 deficiency, 17-alpha-hydroxylase deficiency, gonadal dysgenesis, testicular regression syndrome, LH receptor defects, 5-alpha-reductase type 2 deficiency, mullerian agenesis, primary ovarian insufficiency, hypogonadotropic hypogonadism and turner syndrome.
Differentiating 17 alpha-hydroxylase deficiency from other Diseases
17 alpha-hydroxylase deficiency must be differentiated from diseases with primary amenorrhea. Some of these causes include androgen insensitivity syndrome, 3 beta-hydroxysteroid dehydrogenase deficiency, gonadal dysgenesis, testicular regression syndrome, LH receptor defects, 5-alpha-reductase type 2 deficiency, mullerian agenesis, primary ovarian insufficiency, hypogonadotropic hypogonadism and turner syndrome.[1][2][3][4][5][6][7][8]
Differential diagnosis for primary amenorrhea:
Disease name | Cause | Differentiating | ||||||
---|---|---|---|---|---|---|---|---|
Findings | Uterus | Breast development | Testosterone | LH | FSH | Karyotyping | ||
17-alpha-hydroxylase deficiency |
|
No |
No |
↓ |
Normal |
Normal |
||
3 beta-hydroxysteroid dehydrogenase deficiency |
|
Yes in female |
Yes in female |
↓ |
Normal |
Normal |
||
Gonadal dysgenesis |
|
|
Yes |
Yes |
↓ |
↑ |
↑ |
|
Testicular regression syndrome |
|
|
No |
No |
↓ |
↑ |
↑ |
|
LH receptor defects |
|
No |
No |
↓ |
↑ |
↑ |
||
5-alpha-reductase type 2 deficiency |
|
No |
No |
Normal male range |
High to normal |
High to normal |
||
Androgen insensitivity syndrome |
|
|
No |
Yes |
Normal male range |
Normal |
Normal |
|
Mullerian agenesis |
|
No |
Yes |
Normal female range |
Normal |
Normal |
||
Primary ovarian insufficiency |
|
|
Yes |
Yes |
Normal female range |
↑ |
↑ |
|
Hypogonadotropic hypogonadism |
|
|
Yes |
No |
Normal female range |
Low |
Normal |
|
|
|
Yes |
Yes |
Normal female range |
↑ |
↑ |
17 alpha-hydroxylase deficiency must be differentiated from diseases that cause ambiguous genitalia:[9][10]
Disease name | Steroid status | Important clinical findings | |
---|---|---|---|
Increased | Decreased | ||
Classic type of 21-hydroxylase deficiency |
|
| |
11-β hydroxylase deficiency |
|
| |
17-α hydroxylase deficiency |
| ||
3 beta-hydroxysteroid dehydrogenase deficiency |
| ||
Gestational hyperandrogenism |
|
|
17 alpha-hydroxylase deficiency can cause low reninemic hypertension and should be differentiate from other causes of pseudohyperaldosteronism (low renin):
Pseudohyperaldosteronism causes | Disease | Etiology | Clinical features | Labratory | Treatment | |||
---|---|---|---|---|---|---|---|---|
Elevated mineralocorticoid | Renin | Aldosterone | Other | |||||
Endogenous causes | 17 alpha-hydroxylase deficiency |
|
|
Deoxycorticosterone (DOC) | ↓ | ↓ | Cortisol ↓ | Corticosteroids |
11β-hydroxylase deficiency |
|
|
Cortisol ↓ | |||||
Apparent mineralocorticoid excess syndrome (AME) | Genetic or acquired defect of 11-HSD gene
|
|
Cortisol has mineralocorticoid effects | ↓ | ↓ | Urinary free cortisone ↓↓ | Dexamethasone and/or mineralocorticoid blockers | |
Liddle’s syndrome (Pseudohyperaldosteronism type 1) |
|
No extra mineralocorticoid presents, and mutations in Na channels mimic aldosterone mechanism | ↓ | ↓ | Cortisol ↓ | Amiloride or triamterene | ||
Cushing’s syndrome |
|
Rapid weight gain, particularly of the trunk and face with limbs sparing (central obesity)
|
Cortisol has mineralocorticoid effects | ↓ |
|
Urinary free cortisol markedly ↑↑ |
| |
Insensitivity to glucocorticoids (Chrousos syndrome) |
|
|
Deoxycorticosterone (DOC) | ↓ | ↓ | Cortisol | Dexamethasone | |
Cortisol-secreting adrenocortical carcinoma |
|
Rapid weight gain, particularly of the trunk and face with limbs sparing (central obesity)
|
Cortisol has mineralocorticoid effects | ↓ |
|
Urinary free cortisol markedly ↑↑ | Surgery | |
Geller’s syndrome |
|
|
Progesterone has mineralocorticoid effects | ↓ | ↓ | - | mineralocorticoid blockers | |
Gordon’s syndrome (Pseudohypoaldosteronism type 2) |
|
|
No excess mineralocorticoid; an increased activity of the thiazide-sensitive Na–Cl co-transporter in the distal tubule | ↓ | Normal | Hyperkalemia | Thiazide diuretics and/or dietary sodium restriction | |
Exogenous causes | Corticosteroids with mineralocorticoid activity |
|
Medications such as fludrocortisone | ↓ | ↓ | - | Change the treatment | |
Licorice ingestion |
|
- | ↓ | ↓ | Moderate ↑ in urinary free cortisol | Discontinue licorice | ||
Grapefruit |
|
- | ↓ | ↓ | - | Discontinue grapefruit | ||
Estrogens | Estrogens can retain sodium and water by different mechanisms, causing:
|
- | ↓ | ↓ | - | Discontinue estrogens |
References
- ↑ Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, Fenichel P, Cartigny M, Pienkowski C, Polak M, Skordis N, Mazen I, Ocal G, Berberoglu M, Reynaud R, Baumann C, Cabrol S, Simon D, Kayemba-Kay's K, De Kerdanet M, Kurtz F, Leheup B, Heinrichs C, Tenoutasse S, Van Vliet G, Grüters A, Eunice M, Ammini AC, Hafez M, Hochberg Z, Einaudi S, Al Mawlawi H, Nuñez CJ, Servant N, Lumbroso S, Paris F, Sultan C (2011). "Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients". J. Clin. Endocrinol. Metab. 96 (2): 296–307. doi:10.1210/jc.2010-1024. PMID 21147889.
- ↑ Moreira AC, Leal AM, Castro M (1990). "Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency". J. Clin. Endocrinol. Metab. 71 (1): 86–91. doi:10.1210/jcem-71-1-86. PMID 2164530.
- ↑ Heremans GF, Moolenaar AJ, van Gelderen HH (1976). "Female phenotype in a male child due to 17-alpha-hydroxylase deficiency". Arch. Dis. Child. 51 (9): 721–3. PMC 1546244. PMID 999330.
- ↑ Biglieri EG (1979). "Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome". J. Steroid Biochem. 11 (1B): 653–7. PMID 226795.
- ↑ Saenger P (1996). "Turner's syndrome". N. Engl. J. Med. 335 (23): 1749–54. doi:10.1056/NEJM199612053352307. PMID 8929268.
- ↑ Bastian C, Muller JB, Lortat-Jacob S, Nihoul-Fékété C, Bignon-Topalovic J, McElreavey K, Bashamboo A, Brauner R (2015). "Genetic mutations and somatic anomalies in association with 46,XY gonadal dysgenesis". Fertil. Steril. 103 (5): 1297–304. doi:10.1016/j.fertnstert.2015.01.043. PMID 25813279.
- ↑ Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (1974). "Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism". Science. 186 (4170): 1213–5. PMID 4432067.
- ↑ Schnitzer JJ, Donahoe PK (2001). "Surgical treatment of congenital adrenal hyperplasia". Endocrinol. Metab. Clin. North Am. 30 (1): 137–54. PMID 11344932.
- ↑ Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT (2007). "Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development". Best Pract. Res. Clin. Endocrinol. Metab. 21 (3): 351–65. doi:10.1016/j.beem.2007.06.003. PMID 17875484.
- ↑ White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr. Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.